Crinetics Pharmaceuticals, Inc.
CRNX
$46.98
$1.974.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -86.13% | 185.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -86.13% | 185.60% | |||
| Cost of Revenue | 590.62% | -82.82% | |||
| Gross Profit | -648.43% | 84.10% | |||
| SG&A Expenses | 4.86% | 40.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.67% | 16.44% | |||
| Operating Income | -10.44% | -15.89% | |||
| Income Before Tax | -12.50% | -19.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.50% | -19.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.50% | -19.49% | |||
| EBIT | -10.44% | -15.89% | |||
| EBITDA | -10.47% | -16.00% | |||
| EPS Basic | -12.00% | -18.62% | |||
| Normalized Basic EPS | -11.99% | -18.61% | |||
| EPS Diluted | -12.00% | -18.62% | |||
| Normalized Diluted EPS | -11.99% | -18.61% | |||
| Average Basic Shares Outstanding | 0.45% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.45% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||